Clinical Research Sites for the MACS/WIHS Combined Cohort Study (MACS/WIHS-CCS) - Baltimore/Wash DC Center

摘要 2023年基金年要求OAR战略资金进行高通量蛋白质组学 研究MWCCS患者心功能不全的蛋白质特征的测量。 之前采集的完成基线超声心动图的参与者的血液样本 在互委会访问67-71次(n=1195)和WIHS访问44-50次(n=1655)将用于测量 蛋白质组学，以便发现蛋白质标记物。MACS和WIHS中的基因数据 将利用蛋白质数量性状进行孟德尔随机化分析 基因座，允许因果推断和选择药物治疗的蛋白质靶标。这 补充资金将支持与以下国家卫生研究院高度优先事项相对应的艾滋病毒/艾滋病研究 指定的艾滋病专题：(1)与艾滋病毒有关的合并症；(2)涉及 临床转化研究、心血管疾病、蛋白质组学、多组学和健康 差异；以及(3)培训下一代艾滋病毒调查员的组学和 合并症研究。

Abstract Fund Year 2023 OAR Strategic Funds are requested to perform high-throughput proteomic measurements to investigate the protein signatures of cardiac dysfunction in MWCCS. Previously collected blood specimens in participants who completed baseline echocardiography in MACS Visits 67-71 (n=1195) and WIHS Visits 44-50 (n=1655) will be used to measure proteomics in order to permit discovery of protein markers. Genotypic data in MACS and WIHS will be leveraged to conduct Mendelian randomization analysis using protein quantitative trait loci, allowing causal inference and selection of protein targets for pharmacotherapy. This supplement will support HIV/AIDS research corresponding to the following NIH high-priority AIDS-designated topics: (1) HIV-associated comorbidities; (2) cross-cutting areas involving clinical translational research, cardiovascular disease, proteomics, multi-omics, and health disparities; and (3) training of the next generation of HIV investigators in omics and comorbidities research.